Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.

Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA.

J Immunother Cancer. 2019 Nov 6;7(1):285. doi: 10.1186/s40425-019-0792-9.

2.

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.

Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA.

J Immunother Cancer. 2019 Aug 8;7(1):213. doi: 10.1186/s40425-019-0689-7. Erratum in: J Immunother Cancer. 2019 Nov 6;7(1):285.

3.

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK.

Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720. doi: 10.1016/S2468-1253(19)30189-X. Epub 2019 Jul 9.

PMID:
31300360
4.

Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.

Madariaga A, Rustin GJS, Buckanovich RJ, Trent JC, Oza AM.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e152-e166. doi: 10.1200/EDBK_238755. Epub 2019 May 17. Review.

5.

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.

Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC.

Lancet Oncol. 2019 Jun;20(6):837-848. doi: 10.1016/S1470-2045(19)30153-6. Epub 2019 May 8.

PMID:
31078463
6.

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.

Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG.

Cancer. 2019 Jul 15;125(14):2445-2454. doi: 10.1002/cncr.32084. Epub 2019 Apr 29.

7.

How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.

Van Tine BA, Trent JC.

Curr Med Res Opin. 2019 Apr;35(4):623-629. doi: 10.1080/03007995.2019.1570768. Epub 2019 Feb 4.

PMID:
30652922
8.

Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-Risk Extremity Soft Tissue Sarcoma.

Baldini EH, Le Cesne A, Trent JC.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:910-915. doi: 10.1200/EDBK_201421. Review.

9.

A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas.

Espejo AP, Ramdial JL, Wilky BA, Kerr DA, Trent JC.

Rare Tumors. 2018 Jul 18;10:2036361318787626. doi: 10.1177/2036361318787626. eCollection 2018.

10.

Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER.

Ramey SJ, Yechieli R, Zhao W, Kodiyan J, Asher D, Chinea FM, Patel V, Reis IM, Wang L, Wilky BA, Subhawong T, Trent JC 2nd.

Cancer Med. 2018 Sep;7(9):4228-4239. doi: 10.1002/cam4.1625. Epub 2018 Jul 20.

11.

Use of Tyrosine Kinase Inhibitors in Patients With GI Stromal Tumor Who Are Pregnant or Considering Pregnancy: Driver Mutations and Circulating Tumor DNA.

Florou V, Ramdial JL, Trent JC.

J Clin Oncol. 2018 Sep 1;36(25):2659-2660. doi: 10.1200/JCO.2018.79.0501. Epub 2018 May 31. No abstract available.

PMID:
29851548
12.

A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib.

Alavi SN, Florou V, Tinoco G, Trent JC, Wilky BA.

Discov Med. 2018 Mar;25(137):131-144. Review.

13.

Latest advances in adult gastrointestinal stromal tumors.

Florou V, Wilky BA, Trent JC.

Future Oncol. 2017 Oct;13(24):2183-2193. doi: 10.2217/fon-2017-0245. Epub 2017 Oct 6. Review.

PMID:
28984483
14.

Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy.

Li L, Eid JE, Paz AC, Trent JC.

BioDrugs. 2017 Oct;31(5):379-392. doi: 10.1007/s40259-017-0237-2. Review.

PMID:
28840584
15.

Current status of immunotherapy for gastrointestinal stromal tumor.

Tan Y, Trent JC, Wilky BA, Kerr DA, Rosenberg AE.

Cancer Gene Ther. 2017 Mar;24(3):130-133. doi: 10.1038/cgt.2016.58. Epub 2017 Feb 10. Review.

PMID:
28186088
16.

Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic.

Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, Pappo AS, Schiffman JD, Wright J, Trent JC, Pacak K, Stratakis CA, Helman LJ, La Quaglia MP.

J Clin Oncol. 2017 Feb 10;35(5):523-528. doi: 10.1200/JCO.2016.68.6733. Epub 2016 Dec 28.

17.

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.

Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK.

J Transl Med. 2016 Dec 14;14(1):339.

18.

PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms.

Charville GW, Varma S, Forgó E, Dumont SN, Zambrano E, Trent JC, Lazar AJ, van de Rijn M.

Am J Surg Pathol. 2016 Oct;40(10):1305-15. doi: 10.1097/PAS.0000000000000717.

PMID:
27526298
19.

Desmoid fibromatosis: MRI features of response to systemic therapy.

Sheth PJ, Del Moral S, Wilky BA, Trent JC, Cohen J, Rosenberg AE, Temple HT, Subhawong TK.

Skeletal Radiol. 2016 Oct;45(10):1365-73. doi: 10.1007/s00256-016-2439-y. Epub 2016 Aug 9.

PMID:
27502790
20.

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, Trent JC, von Mehren M, Wright JA, Schiffman JD, Raygada M, Pacak K, Meltzer PS, Miettinen MM, Stratakis C, Janeway KA, Helman LJ.

JAMA Oncol. 2016 Jul 1;2(7):922-8. doi: 10.1001/jamaoncol.2016.0256.

21.

A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.

Montero AJ, Kwon D, Flores A, Kovacs K, Trent JC, Benedetto P, Rocha-Lima C, Merchan JR.

Clin Cancer Res. 2016 Jul 1;22(13):3209-17. doi: 10.1158/1078-0432.CCR-15-2184. Epub 2016 Feb 10.

22.

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.

Li L, Paz AC, Wilky BA, Johnson B, Galoian K, Rosenberg A, Hu G, Tinoco G, Bodamer O, Trent JC.

PLoS One. 2015 Sep 14;10(9):e0133813. doi: 10.1371/journal.pone.0133813. eCollection 2015.

23.

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma.

Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, Bagaria SP, Jones RL, Sherman C, Kozak KR, Cortese CM, McFarland T, Trent JC, Maki RG.

Rare Tumors. 2015 May 21;7(2):5992. doi: 10.4081/rt.2015.5992. eCollection 2015 May 5.

24.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Trent JC.

Oncologist. 2015 Jul;20(7):823-30. doi: 10.1634/theoncologist.2014-0471. Epub 2015 Jun 12. Review.

25.

The immune system and gastrointestinal stromal tumor: a wealth of opportunities.

Tan Y, Garcia-Buitrago MT, Trent JC, Rosenberg AE.

Curr Opin Oncol. 2015 Jul;27(4):338-42. doi: 10.1097/CCO.0000000000000201. Review.

PMID:
26049274
26.

The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.

Tinoco G, Wilky BA, Paz-Mejia A, Rosenberg A, Trent JC.

Am Soc Clin Oncol Educ Book. 2015:e648-55. doi: 10.14694/EdBook_AM.2015.35.e648. Review.

27.

Rhabdomyosarcoma in adults: new perspectives on therapy.

Ruiz-Mesa C, Goldberg JM, Coronado Munoz AJ, Dumont SN, Trent JC.

Curr Treat Options Oncol. 2015 Jun;16(6):27. doi: 10.1007/s11864-015-0342-8. Review.

PMID:
25975442
28.

Managing GIST in the imatinib era: optimization of adjuvant therapy.

Trent JC, Subramanian MP.

Expert Rev Anticancer Ther. 2014 Dec;14(12):1445-59. doi: 10.1586/14737140.2014.952284. Epub 2014 Oct 23. Review.

PMID:
25340579
29.

Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Dumont SN, Yang D, Dumont AG, Reynoso D, Blay JY, Trent JC.

Mol Oncol. 2014 Dec;8(8):1458-68. doi: 10.1016/j.molonc.2014.05.016. Epub 2014 Jun 10.

30.

Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors.

Bednarski BK, Araujo DM, Yi M, Torres KE, Lazar A, Trent JC, Cormier JN, Pisters PW, Lev DC, Pollock RE, Feig BW, Hunt KK.

Ann Surg Oncol. 2014 Aug;21(8):2499-505. doi: 10.1245/s10434-014-3632-7. Epub 2014 Mar 18.

31.

Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients.

Dumont SN, Araujo DM, Munsell MF, Salganick JA, Dumont AG, Raymond KA, Linassier C, Patel S, Benjamin RS, Trent JC.

Cancer Med. 2013 Aug;2(4):553-63. doi: 10.1002/cam4.92. Epub 2013 Jul 15.

32.

Pazopanib in sarcomas: expanding the PALETTE.

Wilky BA, Meyer CF, Trent JC.

Curr Opin Oncol. 2013 Jul;25(4):373-8. doi: 10.1097/CCO.0b013e3283622d3a. Review.

33.

The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis.

Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM.

Clin Sarcoma Res. 2013 May 11;3(1):7. doi: 10.1186/2045-3329-3-7.

34.

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.

Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R.

Oncotarget. 2013 Feb;4(2):310-5.

35.

Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy.

Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, Lòpez-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJ.

Clin Sarcoma Res. 2012 Dec 29;2(1):25. doi: 10.1186/2045-3329-2-25.

36.

Extraskeletal myxoid chondrosarcoma with small bowel metastasis causing bowel obstruction.

Bustinza-Linares E, Socola F, Ernani V, Miller SA, Trent JC.

Case Rep Oncol Med. 2012;2012:621025. doi: 10.1155/2012/621025. Epub 2012 Nov 18.

37.

Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors.

Dumont AG, Yang Y, Reynoso D, Katz D, Trent JC, Hughes DP.

Carcinogenesis. 2012 Sep;33(9):1674-83. doi: 10.1093/carcin/bgs221. Epub 2012 Jul 4.

38.

Cardiac tumors in a tertiary care cancer hospital: clinical features, echocardiographic findings, treatment and outcomes.

Yusuf SW, Bathina JD, Qureshi S, Kaynak HE, Banchs J, Trent JC, Ravi V, Daher IN, Swafford J.

Heart Int. 2012 Feb 3;7(1):e4. doi: 10.4081/hi.2012.e4. Epub 2012 Feb 13.

39.

The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.

Dumont AG, Dumont SN, Trent JC.

Chin J Cancer. 2012 Jul;31(7):327-34. doi: 10.5732/cjc.012.10032. Epub 2012 May 24. Review.

40.

Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study.

Hatoum HT, Lin SJ, Sasane M, Trent JC.

Curr Med Res Opin. 2012 May;28(5):805-14. doi: 10.1185/03007995.2012.685928. Epub 2012 Apr 30.

PMID:
22506625
41.

Exploiting antitumor immunity to overcome relapse and improve remission duration.

Chen LL, Chen X, Choi H, Sang H, Chen LC, Zhang H, Gouw L, Andtbacka RH, Chan BK, Rodesch CK, Jimenez A, Cano P, Jones KA, Oyedeji CO, Martins T, Hill HR, Schumacher J, Willmore C, Scaife CL, Ward JH, Morton K, Randall RL, Lazar AJ, Patel S, Trent JC, Frazier ML, Lin P, Jensen P, Benjamin RS.

Cancer Immunol Immunother. 2012 Jul;61(7):1113-24. doi: 10.1007/s00262-011-1185-1. Epub 2011 Dec 24.

42.

PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.

Dumont SN, Lazar AJ, Bridge JA, Benjamin RS, Trent JC.

J Cancer Res Clin Oncol. 2012 Feb;138(2):213-20. doi: 10.1007/s00432-011-1089-7. Epub 2011 Nov 17.

43.

R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.

Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R.

PLoS One. 2011;6(10):e26060. doi: 10.1371/journal.pone.0026060. Epub 2011 Oct 11.

44.

A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.

Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M.

Ann Oncol. 2012 May;23(5):1335-40. doi: 10.1093/annonc/mdr442. Epub 2011 Oct 12.

45.

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.

Eisenberg BL, Trent JC.

Int J Cancer. 2011 Dec 1;129(11):2533-42. doi: 10.1002/ijc.26234. Review.

46.

Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant.

Hanson JA, Trent JC, Yang D, Cooper K.

Int J Surg Pathol. 2011 Oct;19(5):653-7. doi: 10.1177/1066896911404413. Epub 2011 Apr 28.

PMID:
21531698
47.

Gastrointestinal stromal tumor and its targeted therapeutics.

Dupart J, Zhang W, Trent JC.

Chin J Cancer. 2011 May;30(5):303-14. Review.

48.

Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.

Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, Araujo DM, Chen K, Zhang W.

Cancer. 2011 Nov 1;117(21):4925-38. doi: 10.1002/cncr.26116. Epub 2011 Apr 14.

49.

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.

Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM.

Cancer. 2011 Nov 1;117(21):4939-47. doi: 10.1002/cncr.26098. Epub 2011 Apr 8.

50.

A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.

Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC; reGISTry Steering Committee.

Ann Oncol. 2011 Nov;22(11):2523-9. doi: 10.1093/annonc/mdq773. Epub 2011 Apr 4.

PMID:
21464155

Supplemental Content

Loading ...
Support Center